FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

堆栈库

Brain Repair Protocol

Cognitive Enhancementadvanced

80

协同作用

80
Share
肽类

3

平均每日mcg

10,850

级别

advanced

添加时间

May 17, 2026

概述

The Brain Repair Protocol represents the most aggressive peptide approach to neuroregeneration, combining a potent hepatocyte growth factor (HGF) mimetic with established neuroprotective peptides. Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is a modified angiotensin IV analog that was discovered at Washington State University to be approximately 10 million times more potent than BDNF at promoting neuronal connectivity. It acts as an HGF/c-Met receptor agonist, stimulating the formation of new synaptic connections (synaptogenesis) and promoting the survival of existing neurons. In animal models of cognitive impairment, Dihexa restored learning and memory to levels comparable to young control animals. Semax provides complementary neuroprotection through BDNF/NGF upregulation and modulation of the melanocortin system in the brain. Its effects on neuroplasticity — the brain''s ability to form new neural pathways — make it an ideal companion to Dihexa''s synaptogenic activity. While Dihexa builds new connections, Semax ensures the molecular environment (neurotrophic factors, receptor density) supports the survival and strengthening of those connections through long-term potentiation mechanisms. BPC-157 is included for its documented neuroprotective effects, including modulation of the dopaminergic system, protection against excitotoxic damage (NMDA receptor modulation), and promotion of nerve growth factor expression. In animal models, BPC-157 has shown efficacy against traumatic brain injury, counteracted the effects of neurotoxins, and promoted peripheral nerve regeneration. The three-peptide combination addresses neuroregeneration from multiple angles: structural connectivity (Dihexa), neurotrophic environment (Semax), and neuroprotection/repair (BPC-157). This stack is classified as advanced and researcher-only due to Dihexa''s extreme potency, complete lack of human safety data, and theoretical concerns about its proliferative potential. It is not recommended without medical supervision and thorough risk assessment.

给药方案

Dihexa

Every day· oral

了解更多关于Dihexa →

10,000 mcg

每剂

Semax

Every day· nasal

了解更多关于Semax →

600 mcg

每剂

BPC-157

Every day· subcutaneous

了解更多关于BPC-157 →

250 mcg

每剂

目标与证据

NeurogenesisMemory repairCognitive declineBrain injuryNeuroprotection
证据等级:动物研究

警告

  • Dihexa is a potent HGF mimetic with NO human trials. Extremely experimental. Semax has Russian approval. BPC-157 was removed from FDA Category 2 (April 2026) but remains under PCAC review — not legal to compound yet. This stack is for researchers only.

Comments

Sign in to join the discussion

免责声明: 此堆栈由社区提交,仅供研究用途。Peptide Contacts不对提交的堆栈的安全性或有效性进行验证。使用任何肽类协议前,请务必咨询合格的医疗专业人员。